Related references
Note: Only part of the references are listed.Activating mutations in human acute megakaryoblastic leukemia
Sebastien Malinge et al.
BLOOD (2008)
Acute lymphoblastic leukaemia
Ching-Hon Pui et al.
LANCET (2008)
Identification and characterization of novel AML1-ETO fusion transcripts in pediatric t(8;21) acute myeloid leukemia: a report from the Children's Oncology Group
K. M. LaFiura et al.
ONCOGENE (2008)
The role of the proto-oncogene ETS2 in acute megakaryocytic leukemia biology and therapy
Y. Ge et al.
LEUKEMIA (2008)
Acute Megakaryoblastic leukemia in Down syndrome
Johann K. Hitzler
PEDIATRIC BLOOD & CANCER (2007)
Prognostic factors and outcome of recurrence in childhood acute myeloid leukemia
Jeffrey E. Rubnitz et al.
CANCER (2007)
Prognostic factors and risk-based therapy in pediatric acute myeloid leukemia
Soheil Meshinchi et al.
ONCOLOGIST (2007)
Targeting receptor tyrosine kinase signaling in acute myeloid leukemia
Kathrin T. Doepfner et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2007)
Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21):: A Cancer and Leukemia Group B study
Peter Paschka et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Prospective analysis of TEL/AML1-positive patients treated on Dana-Farber Cancer Institute consortium protocol 95-01
Mignon L. Loh et al.
BLOOD (2006)
Rosetta error model for gene expression analysis
L Weng et al.
BIOINFORMATICS (2006)
Prognostic impact of c-KIT mutations in core binding factor leukemas:: an Italian retrospective study
R Cairoli et al.
BLOOD (2006)
KIT mutations, and not FLT3 internal tandem duplication, are strongly associated with a poor prognosis in pediatric acute myeloid leukemia with t(8;21):: a study of the Japanese Childhood AML Cooperative Study Group
A Shimada et al.
BLOOD (2006)
KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival
S Schnittger et al.
BLOOD (2006)
Identification of distinct molecular phenotypes in acute megakaryoblastic leukemia by gene expression profiling
JP Bourquin et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Differential gene expression, GATA1 target genes, and the chemotherapy sensitivity of Down syndrome megakaryocytic leukemia
YB Ge et al.
BLOOD (2006)
Adult acute megakaryocytic leukemia: an analysis of 37 patients treated at MD Anderson Cancer Center
Y Oki et al.
BLOOD (2006)
Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia
A. M. Martelli et al.
LEUKEMIA (2006)
Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies
Ting-Chao Chou
PHARMACOLOGICAL REVIEWS (2006)
Essential role for the p110δ isoform in phosphoinositide 3-kinase activation and cell proliferation in acute myeloid leukemia
P Sujobert et al.
BLOOD (2005)
Acute megakaryoblastic leukemia in children and adolescents, excluding Down's syndrome: improved outcome with intensified induction treatment
D Reinhardt et al.
LEUKEMIA (2005)
AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity
U Creutzig et al.
LEUKEMIA (2005)
GATA1, cytidine deaminase, and the high cure rate of Down syndrome children with acute megakaryocytic leukemia
YB Ge et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
Mortality in overweight and children with acute myeloid underweight leukemia
BJ Lange et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2005)
Gene expression profiling of pediatric acute myelogenous leukemia
ME Ross et al.
BLOOD (2004)
The 8; 21 translocation in leukemogenesis
LF Peterson et al.
ONCOGENE (2004)
Increased age at diagnosis has a significantly negative effect on outcome in children with down syndrome and acute myeloid leukemia: A report from the Children's Cancer Group Study 2891
AS Gamis et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Biology, clinical, and hematologic features of acute megakaryoblastic leukemia in children
R Paredes-Aguilera et al.
AMERICAN JOURNAL OF HEMATOLOGY (2003)
Transcriptional regulation of the cystathionine-β-synthase gene in Down syndrome and non-Down syndrome megakaryocytic leukemia cell lines
YB Ge et al.
BLOOD (2003)
Amplification of AML1 in acute lymphoblastic leukemia is associated with a poor outcome
HM Robinson et al.
LEUKEMIA (2003)
Acute megakaryoblastic leukemia: experience of GIMEMA trials
L Pagano et al.
LEUKEMIA (2002)
In vitro analyses of known and novel RUNX1/AML1 mutations in dominant familial platelet disorder with predisposition to acute myelogenous leukemia: implications for mechanisms of pathogenesis
J Michaud et al.
BLOOD (2002)
Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome
CM Zwaan et al.
BLOOD (2002)
Biology and outcome of childhood acute megakaryoblastic leukemia: a single institution's experience
UH Athale et al.
BLOOD (2001)
Repression of human reduced folate carrier gene expression by wild type p53
BC Ding et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
An effective chemotherapeutic regimen for acute myeloid leukemia and myelodysplastic syndrome in children with Down's syndrome
S Kojima et al.
LEUKEMIA (2000)
Cellular cytotoxic drug sensitivity in children with acute leukemia and Down's syndrome:: an explanation to differences in clinical outcome?
BM Frost et al.
LEUKEMIA (2000)
Molecular and clinical advances in core binding factor primary acute myeloid leukemia: A paradigm for translational research in malignant hematology
G Marcucci et al.
CANCER INVESTIGATION (2000)
Share Paper
